Dr Reddys Laboratories Ltd 6-K, filed Apr 1, 2021
Dr Reddys Laboratories Ltd (RDY)
About this 6-K
Dr Reddys Laboratories Ltd filed this 6-K on April 1, 2021.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
April, 2021
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
|
Exhibit |
Description of Exhibits | |
| 99.1 | Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligation and Disclosures Requirements) Regulations, 2015. | |
| 99.2 | Newspaper Publication | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DR. REDDY’S LABORATORIES LIMITED (Registrant) | ||
| Date: April 1, 2021 | By: | /s/ Sandeep Poddar |
| Name: Sandeep Poddar | ||
| Title: Company Secretary | ||
Exhibit 99.1
 |
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, CIN : L85195TG1984PLC004507
Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com |
April 1, 2021
To,
The Secretary
BSE Limited
National Stock Exchange of lndia Ltd.
New York Stock Exchange Inc.
NSE IFSC Limited
Dear Sir/ Madam,
Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligation and Disclosures Requirements) Regulations, 2015.
We would like to inform you that DigiHealth Technologies LLP, the wholly owned entity of our Indian investee entity i.e. ABCD Technologies LLP (to be renamed as IndoHealth Services LLP), has agreed to acquire 100% ownership interest in Pharmarack Technologies Private Limited in tranches. The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFO/CMD/4/2015 dated September 9, 2015 are given in Annexure A to this letter.
This is for your information and record.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
Encl: As above
ANNEXURE – A
Details as per the Securities and Exchange Board of India circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015
| Sr. No. | Particulars | Details |
| a. | Name of the target entity, details in brief such as size, turnover etc. |
(i) Name of the Target Entity: Pharmarack Technologies Private Limited (“Pharmarack”).
(ii) Details of the Target Entity: Pharmarack operates a digital platform aimed at integrating and solving problems across the pharmaceutical supply chain. Its platform offers/ proposes to offer products across supply chain including order automation, fulfilment services & optimization, digital payments, working capital optimization, analytics and market insights. |
| b. | Whether the acquisition would fall within related party transaction(s)and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is one at "arms-length" |
Not a related party transaction.
|
| c. |
Industry to which the entity being acquired belongs |
Healthcare industry. |
| d. | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line' of business of the listed entity) | A step by ABCD Technologies LLP (to be renamed as IndoHealth Services LLP) towards the initiative with an objective to facilitate, enable and promote efficiency and Good Distribution Practices (‘GDP’) including digitizing healthcare infrastructure in India, inter alia, in support of the National Digital Health Mission of Government of India (‘Business’). The acquisition is and will be done by its wholly owned entity DigiHealth Technologies LLP. |
| e. | Brief details of any governmental or regulatory approvals required for the acquisition | Not Applicable |
| f. | Indicative time period for completion of the acquisition |
The upfront acquisition of 91.8% of shareholding in Pharmarack is expected to be completed by April 30, 2021 by purchase of shares from multiple existing shareholders in various lots. The remaining 8.2% of the shareholding in Pharmarack is likely to be acquired in multiple tranches over the next 5 (five) years. |
| g. | Nature of consideration - whether cash consideration or share swap and details of the same | Cash consideration payable by DigiHealth Technologies LLP. |
| h. | Cost of acquisition or the price at which the shares are acquired |
Cost of acquisition to DigiHealth Technologies LLP for upfront acquisition of 91.8% is INR 111 crores.
Cost of acquisition of remaining shareholding shall be linked to future performance of Pharmarack. |
| i. |
Percentage of shareholding / control acquired and / or number of shares acquired |
Please refer to the response provided in point (f) above. |
| j. | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) |
(i) About the entity: Pharmarack operates a digital platform aimed at integrating and solving problems across the pharmaceutical supply chain. Its platform offers/ proposes to offer products across supply chain including order automation, fulfilment services & optimization, digital payments, working capital optimization, analytics and market insights.
(ii) Date of Incorporation: September 21, 2015
(iii) Turnover history of last 3 years: 2019-2020: INR 4,04,52,773/- 2018-2019: INR 2,14,87,907/- 2017-2018: INR 64,90,444/-
(iv) Country: India |
Exhibit 99.2
 |
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, CIN : L85195TG1984PLC004507
Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com |
March 31, 2021
The Secretary
BSE
National Ltd. Stock Exchange of India Ltd.
New York Stock Exchange Inc.
NSE IFSC Ltd.
Dear Sir/Madam,
Sub: Board Meeting Notice - Advertisement
Further to our intimation dated March 29, 2021, please find enclosed herewith copies of the newspaper advertisements published on March 31, 2021, regarding notice of Board meeting scheduled to be held on Friday, May 14, 2021.
This is for your information and record.
With regards,
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
Encl: A/a
